Medical Education - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/190

Filters

2016 - 2019 1 2020 - 2023 1
Reset filters

Settings
Statistics
Citations
Author: McNally, Orla × Author: Mileshkin, Linda × Author: Scott, Clare × Type: Journal Article ×

Search Results

Now showing 1 - 2 of 2
  • Item
    No Preview Available
    Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer
    Burdett, NL ; Willis, MO ; Alsop, K ; Hunt, AL ; Pandey, A ; Hamilton, PT ; Abulez, T ; Liu, X ; Hoang, T ; Craig, S ; Fereday, S ; Hendley, J ; Garsed, DW ; Milne, K ; Kalaria, S ; Marshall, A ; Hood, BL ; Wilson, KN ; Conrads, KA ; Pishas, K ; Ananda, S ; Scott, CL ; Antill, Y ; McNally, O ; Mileshkin, L ; Hamilton, A ; Au-Yeung, G ; Devereux, L ; Thorne, H ; Bild, A ; Bateman, NW ; Maxwell, GL ; Chang, JT ; Conrads, TPP ; Nelson, BH ; Bowtell, DDL ; Christie, ELL (NATURE PORTFOLIO, 2023-03)
    High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, while most such tumors are sensitive to initial treatment, acquired resistance is common. We undertook a multiomics approach to interrogate molecular diversity in end-stage disease, using multiple autopsy samples collected from 15 women with HR-deficient HGSC. Patients had polyclonal disease, and several resistance mechanisms were identified within most patients, including reversion mutations and HR restoration by other means. We also observed frequent whole-genome duplication and global changes in immune composition with evidence of immune escape. This analysis highlights diverse evolutionary changes within HGSC that evade therapy and ultimately overwhelm individual patients.
  • Item
    Thumbnail Image
    RAD51B in Familial Breast Cancer
    Pelttari, LM ; Khan, S ; Vuorela, M ; Kiiski, JI ; Vilske, S ; Nevanlinna, V ; Ranta, S ; Schleutker, J ; Winqvist, R ; Kallioniemi, A ; Doerk, T ; Bogdanova, NV ; Figueroa, J ; Pharoah, PDP ; Schmidt, MK ; Dunning, AM ; Garcia-Closas, M ; Bolla, MK ; Dennis, J ; Michailidou, K ; Wang, Q ; Hopper, JL ; Southey, MC ; Rosenberg, EH ; Fasching, PA ; Beckmann, MW ; Peto, J ; dos-Santos-Silva, I ; Sawyer, EJ ; Tomlinson, I ; Burwinkel, B ; Surowy, H ; Guenel, P ; Truong, T ; Bojesen, SE ; Nordestgaard, BG ; Benitez, J ; Gonzalez-Neira, A ; Neuhausen, SL ; Anton-Culver, H ; Brenner, H ; Arndt, V ; Meindl, A ; Schmutzler, RK ; Brauch, H ; Bruening, T ; Lindblom, A ; Margolin, S ; Mannermaa, A ; Hartikainen, JM ; Chenevix-Trench, G ; Van Dyck, L ; Janssen, H ; Chang-Claude, J ; Rudolph, A ; Radice, P ; Peterlongo, P ; Hallberg, E ; Olson, JE ; Giles, GG ; Milne, RL ; Haiman, CA ; Schumacher, F ; Simard, J ; Dumont, M ; Kristensen, V ; Borresen-Dale, A-L ; Zheng, W ; Beeghly-Fadiel, A ; Grip, M ; Andrulis, IL ; Glendon, G ; Devilee, P ; Seynaeve, C ; Hooning, MJ ; Collee, M ; Cox, A ; Cross, SS ; Shah, M ; Luben, RN ; Hamann, U ; Torres, D ; Jakubowska, A ; Lubinski, J ; Couch, FJ ; Yannoukakos, D ; Orr, N ; Swerdlow, A ; Darabi, H ; Li, J ; Czene, K ; Hall, P ; Easton, DF ; Mattson, J ; Blomqvist, C ; Aittomaki, K ; Nevanlinna, H ; Brusgaard, K (PUBLIC LIBRARY SCIENCE, 2016-05-05)
    Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 with the risk of female breast cancer and rs1314913 with the risk of male breast cancer. The aim of this study was to investigate the role of RAD51B variants in breast cancer predisposition, particularly in the context of familial breast cancer in Finland. We sequenced the coding region of RAD51B in 168 Finnish breast cancer patients from the Helsinki region for identification of possible recurrent founder mutations. In addition, we studied the known rs999737, rs2588809, and rs1314913 SNPs and RAD51B haplotypes in 44,791 breast cancer cases and 43,583 controls from 40 studies participating in the Breast Cancer Association Consortium (BCAC) that were genotyped on a custom chip (iCOGS). We identified one putatively pathogenic missense mutation c.541C>T among the Finnish cancer patients and subsequently genotyped the mutation in additional breast cancer cases (n = 5259) and population controls (n = 3586) from Finland and Belarus. No significant association with breast cancer risk was seen in the meta-analysis of the Finnish datasets or in the large BCAC dataset. The association with previously identified risk variants rs999737, rs2588809, and rs1314913 was replicated among all breast cancer cases and also among familial cases in the BCAC dataset. The most significant association was observed for the haplotype carrying the risk-alleles of all the three SNPs both among all cases (odds ratio (OR): 1.15, 95% confidence interval (CI): 1.11-1.19, P = 8.88 x 10-16) and among familial cases (OR: 1.24, 95% CI: 1.16-1.32, P = 6.19 x 10-11), compared to the haplotype with the respective protective alleles. Our results suggest that loss-of-function mutations in RAD51B are rare, but common variation at the RAD51B region is significantly associated with familial breast cancer risk.